Adma Biologics (ADMA) Cash & Equivalents (2011 - 2025)

Adma Biologics has reported Cash & Equivalents for 15 years, with the latest figure at $87.6 million in Q4 2025.

• For the quarter ending Q4 2025, Cash & Equivalents fell 15.04% year-over-year to $87.6 million; the trailing twelve-month figure through Dec 2025 stood at $87.6 million (down 15.04% YoY), and the FY2025 full-year result was $87.6 million, down 15.04% from the prior year.
• Cash & Equivalents for Q4 2025 stood at $87.6 million, up from $61.4 million in the prior quarter.
• The five-year high for Cash & Equivalents was $103.1 million in Q4 2024, with the low at $34.4 million in Q3 2021.
• Historically, Cash & Equivalents has averaged $66.2 million across 5 years, with a median of $65.9 million in 2023.
• Annual changes were most pronounced in 2021 — Cash & Equivalents tumbled 42.34% — and 2023, when it jumped 112.57%.
• Adma Biologics' Cash & Equivalents stood at $51.1 million in 2021, then jumped by 69.36% to $86.5 million in 2022, then slumped by 40.65% to $51.4 million in 2023, then surged by 100.86% to $103.1 million in 2024, then decreased by 15.04% to $87.6 million in 2025.
• The last three Cash & Equivalents figures came in at $87.6 million (Q4 2025), $61.4 million (Q3 2025), and $90.3 million (Q2 2025), per Business Quant data.